It will be interesting to see which drug out of the pipeline they try to get the partnership for. And whether they keep the US rights to that particular drug. I know they'd like to keep 100% of CDX-110 and CDX-011 if feasible.
You obviously need to work on your reading comprehension skills or IQ. You add nothing to conversations. I stated one thing the first post and I corrected what I stated the 2nd post. You do not provide any information on whether the doctors could or could not use it off label. And if they could, you do not provide any information on if they would or would not. My position is very clear because I have never tried to hide it. Interesting that you feel that you need to hide your positions on stocks. Nobody on this board is controlling whether I make money or not. And I do not try to influence how others choose to make theirs. Or in your case, lose yours.
CDX110 targets EGFRvIII which is also present in some neck, head, oral, and lung cancers. I'm not sure doctors wouldn't try to prescribe it off label when there is no other treatements available for those patients.
CDX011 targets GPNMB which is also present in several different types of tumors. But it will be a long time before we see that adding to the bottom line of CLDX unless they sign a partnership. The good news is that by the time CDX110 gets approved, CDX011 will be in phase 3.
cdx-011 could be cldx's hidden gem.
The Phase 2 study has met its primary endpoint and the results support additional studies in this indication. CDX-011 is an antibody-drug conjugate (ADC) in Phase 2 development for the treatment of melanoma and advanced breast cancer. In addition, in a separate presentation at ASCO, the Company presented the study design for its recently initiated Phase 2 trial of CDX-1307 in bladder cancer. CDX-1307 is an antibody-based cancer vaccine candidate and is being evaluated as a treatment for bladder cancer.
"Both CDX-011 and CDX-1307 have demonstrated tremendous potential for the treatment of the most difficult to treat cancers," said Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics. "Further development is warranted for both candidates and we look forward to reporting additional clinical data in the near future."
The key phrase "LONG TERM"...I doubt that CDX-110 will be presribe off-label: 1. it does not work on everyone; 2. not sure that MD will risk prescribing something that not really proven, maybe as really last resort.
However, if CDX-110 will be approved (and this might happen in 2 years), expected market is $200m-$400m annual sales, it will justify at least $18 p/s.
(2-4 times annual sales)
Much more than 2 years. I see several benefits for the near term though. They could use this to get a new partnership or new leverage. The value of CDX011 goes up with successful treatments for CDX110 just because it is the same approach. I'm curious if CDX110 could be prescribed for breast cancer patients who fit the profile for CDX011. Once CDX110 is approved for use, physicians can prescribe it for other than brain cancer. And the pipeline of Celldex is great for long term investors.